Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer VW, Robinson BD, Park K, Cyrta J, Tagawa ST, Kossai M, Fontugne J, Kim R, Sigaras A, Rao R, Pancirer D, Faltas B, Bareja R, Molina AM, Nanus DM, Rajappa P, Souweidane MM, Greenfield J, Emde AK, Robine N, Elemento O, Sboner A, Demichelis F, Beltran H, Rubin MA, Mosquera JM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00038. Epub 2017 Jun 14.

2.

Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KS, Talenfeld AD, Nanus DM, Tagawa ST, Robinson BD, Rao RA, Pauli C, Bareja R, Beltran LS, Sigaras A, Eng KW, Elemento O, Sboner A, Rubin MA, Beltran H, Mosquera JM.

Cancer. 2018 Mar 1;124(5):1008-1015. doi: 10.1002/cncr.31173. Epub 2017 Dec 19.

PMID:
29266381
3.

Olfactory Epithelial Hamartoma: A New Subtype of Sinonasal Hamartoma.

Kossai M, El Zein S, Wassef M, Guichard JP, Pouliquen C, Herman P, Vérillaud B, Classe M.

Am J Surg Pathol. 2018 Jan;42(1):9-17. doi: 10.1097/PAS.0000000000000967.

PMID:
29076871
4.

Ovarian Cancer: A Heterogeneous Disease.

Kossaï M, Leary A, Scoazec JY, Genestie C.

Pathobiology. 2018;85(1-2):41-49. doi: 10.1159/000479006. Epub 2017 Oct 12.

PMID:
29020678
5.

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].

Campedel L, Kossaï M, Blanc-Durand P, Rouprêt M, Seisen T, Compérat E, Spano JP, Malouf G.

Bull Cancer. 2017 Sep;104(9):789-799. doi: 10.1016/j.bulcan.2017.05.007. Epub 2017 Jun 30. French.

PMID:
28673439
6.

[Glandular lesions of the uterine cervix: Case 3].

Kossai M, Duvillard P, Genestie C.

Ann Pathol. 2016 Jun;36(3):188-91. doi: 10.1016/j.annpat.2016.03.004. Epub 2016 May 25. French. No abstract available.

PMID:
27236348
7.

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.

Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM, Tagawa ST, Marrinucci D, Dittamore R, Scher HI.

Clin Cancer Res. 2016 Mar 15;22(6):1510-9. doi: 10.1158/1078-0432.CCR-15-0137. Epub 2015 Dec 15.

8.

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC.

Cell Rep. 2015 Aug 11;12(6):922-36. doi: 10.1016/j.celrep.2015.07.012. Epub 2015 Jul 30.

9.

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park K, Banfelder J, Prandi D, Madhukar N, Zhang T, Padilla J, Greco N, McNary TJ, Herrscher E, Wilkes D, MacDonald TY, Xue H, Vacic V, Emde AK, Oschwald D, Tan AY, Chen Z, Collins C, Gleave ME, Wang Y, Chakravarty D, Schiffman M, Kim R, Campagne F, Robinson BD, Nanus DM, Tagawa ST, Xiang JZ, Smogorzewska A, Demichelis F, Rickman DS, Sboner A, Elemento O, Rubin MA.

JAMA Oncol. 2015 Jul;1(4):466-74. doi: 10.1001/jamaoncol.2015.1313.

10.

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.

Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B.

Lung Cancer. 2015 Sep;89(3):306-10. doi: 10.1016/j.lungcan.2015.06.014. Epub 2015 Jun 22.

PMID:
26160757
11.

The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA.

Nat Commun. 2014 Nov 21;5:5383. doi: 10.1038/ncomms6383.

12.

Organoid cultures derived from patients with advanced prostate cancer.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y.

Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4.

13.

Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines.

Rabiau N, Kossaï M, Braud M, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ.

Cancer Epidemiol. 2010 Apr;34(2):200-6. doi: 10.1016/j.canep.2009.12.018. Epub 2010 Jan 25.

PMID:
20097631
14.

Aberrant expression of E-cadherin in lobular carcinomas of the breast.

Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, Clarke C, Lakhani SR, Simpson PT.

Am J Surg Pathol. 2008 May;32(5):773-83. doi: 10.1097/PAS.0b013e318158d6c5.

PMID:
18379416

Supplemental Content

Loading ...
Support Center